{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:16:58Z","timestamp":1762899418763},"reference-count":16,"publisher":"Elsevier BV","issue":"49","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T00:00:00Z","timestamp":1510185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.vaccine.2017.05.068","type":"journal-article","created":{"date-parts":[[2017,6,4]],"date-time":"2017-06-04T01:45:41Z","timestamp":1496540741000},"page":"6813-6818","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"PA","title":["Developing and utilizing controlled human models of infection"],"prefix":"10.1016","volume":"35","author":[{"given":"Chad K.","family":"Porter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Louis Bourgeois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Frenck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Prouty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Maier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Riddle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.vaccine.2017.05.068_b0005","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1473-3099(15)00068-7","article-title":"Design, recruitment, and microbiological considerations in human challenge studies","volume":"15","author":"Darton","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2017.05.068_b0010","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/cid\/ciw145","article-title":"Single-dose live oral cholera vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor","volume":"62","author":"Chen","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2017.05.068_b0015","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/infdis\/jiu497","article-title":"Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults","volume":"211","author":"Bernstein","year":"2015","journal-title":"J Infect Dis"},{"issue":"35","key":"10.1016\/j.vaccine.2017.05.068_b0020","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1016\/j.vaccine.2011.05.021","article-title":"A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC)","volume":"29","author":"Porter","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.068_b0025","first-page":"1","article-title":"The Shigella human challenge model","author":"Porter","year":"2012","journal-title":"Epidemiol Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2017.05.068_b0030","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.trsl.2011.12.009","article-title":"Translational research in infectious disease: current paradigms and challenges ahead","volume":"159","author":"Fontana","year":"2012","journal-title":"Transl Res"},{"key":"10.1016\/j.vaccine.2017.05.068_b0035","unstructured":"Brown J, Isaacs D. The World Cafe: shaping our futures through conversations that matter. San Francisco, CA: Berrett-Koehler Publishers; 2005. p. 242."},{"issue":"3","key":"10.1016\/j.vaccine.2017.05.068_b0040","doi-asserted-by":"crossref","first-page":"e0149358","DOI":"10.1371\/journal.pone.0149358","article-title":"An evidenced-based scale of disease severity following human challenge with enteroxigenic Escherichia coli","volume":"11","author":"Porter","year":"2016","journal-title":"PLoS One"},{"issue":"10051","key":"10.1016\/j.vaccine.2017.05.068_b0045","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0140-6736(16)31529-X","article-title":"Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study","volume":"388","author":"Liu","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.05.068_b0050","unstructured":"Fleckenstein J. Blood Group A Antigen Expression Influences Pathogen-Host Interactions and Clinical Outcome Following Infection With Enterotoxigenic Escherichia coli (ANT04). In: Vaccines Against Shigella and ETEC. Washington, DC; 2016."},{"issue":"4","key":"10.1016\/j.vaccine.2017.05.068_b0055","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1128\/IAI.01021-09","article-title":"Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans","volume":"78","author":"Tribble","year":"2010","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.vaccine.2017.05.068_b0060","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/cid\/cit454","article-title":"Lack of homologous protection against campylobacter jejuni CG8421 in a Human Challenge Model","volume":"57","author":"Kirkpatrick","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2017.05.068_b0065","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1128\/IAI.23.3.729-736.1979","article-title":"Immunity to enterotoxigenic Escherichia coli","volume":"23","author":"Levine","year":"1979","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2017.05.068_b0070","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1128\/IAI.66.5.1968-1972.1998","article-title":"Validation of a volunteer model of cholera with frozen bacteria as the challenge","volume":"66","author":"Sack","year":"1998","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2017.05.068_b0075","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/infdis\/159.6.1126","article-title":"Inoculum size in shigellosis and implications for expected mode of transmission","volume":"159","author":"DuPont","year":"1989","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2017.05.068_b0080","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1539-6924.1999.tb01130.x","article-title":"Comparison of six dose-response models for use with food-borne pathogens","volume":"19","author":"Holcomb","year":"1999","journal-title":"Risk Anal"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17307272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17307272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T12:01:03Z","timestamp":1602244863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17307272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":16,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0264410X17307272"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.068","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing and utilizing controlled human models of infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}